MetaboLights

application/xml

ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/m_MTBLS13811_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/m_MTBLS13811_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/a_MTBLS13811_LC-MS_positive_reverse-phase_metabolite_profiling.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/i_Investigation.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/s_MTBLS13811.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/a_MTBLS13811_LC-MS_negative_reverse-phase_metabolite_profiling.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP1_FZTM240323059-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP1_FZTM240323061-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN2_FZTM240323070-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP4_FZTM240323085-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN2_FZTM240323068-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN5_FZTM240323094-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP1_FZTM240323060-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN2_FZTM240323073-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP2_FZTM240323073-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP2_FZTM240323070-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN5_FZTM240323093-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP5_FZTM240323093-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP5_FZTM240323091-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN5_FZTM240323091-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP5_FZTM240323094-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN3_FZTM240323077-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN3_FZTM240323076-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN3_FZTM240323075-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP2_FZTM240323068-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP3_FZTM240323077-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP3_FZTM240323075-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP3_FZTM240323076-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN1_FZTM240323060-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN1_FZTM240323059-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN4_FZTM240323089-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN4_FZTM240323088-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN4_FZTM240323085-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP4_FZTM240323089-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/POS/HF3_CP4_FZTM240323088-1A.rawftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811/FILES/RAW_FILES/NEG/HF3_CN1_FZTM240323061-1A.rawprimary200OKftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13811The normalized data was used to predict themolecular formula based on additive ions,molecular ion peaks and fragment ions.Andthen peaks were matched with the mzCloud(https://www.mzcloud.org/), mzVaultandMassListdatabase to obtain the accuratequalitative and relative quantitativeresults.Statistical analyses were performed using the statistical software R (R versionR-3.4.3),Python (Python 2.7.6 version) and CentOS(CentOS release 6.6),When datawere not normally distributed, normal transformations were attempted using of areanormalization method.MetaboLightsPublicLiquid Chromatography MS - negative - reverse-phaseLiquid Chromatography MS - positive - reverse-phaseUHPLC-MS/MS analyses were performed using a Vanquish UHPLC system(ThermoFisher, Germany) coupled with an Orbitrap Q ExactiveTMHF-X massspectrometer (Thermo Fisher, Germany)in Novogene Co., Ltd. (Beijing, China).Samples were injected onto a HypersilGoldcolumn (100×2.1 mm, 1.9μm) using a12-min linear gradient at a flow rate of 0.2mL/min. The eluents for the positive andnegative polarity modes were eluent A (0.1% FA in Water) and eluent B(Methanol).The solvent gradient was set as follows: 2% B, 1.5 min; 2-85% B, 3 min;85-100% B, 10 min; 100-2% B, 10.1 min; 2% B, 12 min. LGG exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib.ä¸½å©· å¢æµ·åå¤§å¦fecesmass spectrometry assayTissues (100 mg) were individually grounded with liquid nitrogen and thehomogenate wasresuspended with prechilled 80% methanol by well vortex. Thesampleswere incubated on ice for 5 min and then were centrifuged at 15,000 g, 4°Cfor 20 min. Someof supernatant was diluted to final concentration containing 53%methanol by LC-MS grade water.Thesamples were subsequently transferred to a freshEppendorf tube and thenwere centrifuged at 15000 g, 4°C for 20 min. Finally, thesupernatant was injected into the LC-MS/MSsystem analysisMus musculushttps://www.ebi.ac.uk/metabolights/MTBLS13811Siyuan Shen. Hainan University. 1512181782@qq.com.The raw data files generated by UHPLC-MS/MS were processed using the CompoundDiscoverer 3.3 (CD3.3, ThermoFisher) to perform peak alignment, peak picking, andquantitation for each metabolite. The main parameterswere set as follows: peak areawas corrected with the first sample; actual mass tolerance, 5ppm; signal intensitytolerance, 30%; and minimum intensity, et al.After that, peak intensities werenormalized to the total spectral intensity.Treatment1512181782@qq.comFecal samples were collected from mice after a 12-hour fast prior to sacrifice and stored at -80°C.MetabolomicsgefitinibLung Non-Small Cell CarcinomaLactobacillus rhamnosusuntargeted metabolite profilinggefitinibLung Non-Small Cell CarcinomaLactobacillus rhamnosusuntargeted metabolite profilingQ ExactiveTM HF massspectrometer was operated in positive/negative polarity mode with spray voltage of3.5 kV, capillary temperature of 320°C, sheath gas flow rate of 35 psi and aux gasflow rate of 10 L/min, S-lens RF level of 60, Aux gas heater temperature of 350°C.falseLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Fecal metabolomics study in miceAfter screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and in vitro experiments.2026-09-032026-01-31MTBLS13811